Phase 1/2 Trial

WORCESTER, Mass. | June 23, 2026 Leal Therapeutics has announced that the first patient has been dosed in the...

CAMBRIDGE, Mass., June 18, 2026 Prime Medicine, Inc. announced that New Zealand’s Medicines and Medical Devices Safety Authority (Medsafe)...

HOUSTON, June 16, 2026 FibroBiologics announced that the first patients have been dosed in its ongoing Phase 1/2 clinical...

Cambridge, Massachusetts, USA – April 23, 2026 Repertoire Immune Medicines announced a major clinical milestone with the first participant...

Boston, Massachusetts, USA, April 6, 2026 Breakthrough Results in Rare Pediatric Epilepsy In a major advancement for precision neuroscience...

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company, announced the enrollment of the first patient in its...